Shire Moves Up 10 Positions on the Global 100 Sustainability Index
Shire Moves Up 10 Positions on the Global 100 Sustainability Index
Lexington, MA and Zug, Switzerland – January 21, 2016 – Shire plc (LSE: SHP, NASDAQ:
SHPG) announces that it has moved up 10 places in its second year placed in the Global 100 Sustainability Index. This year, Shire was ranked 52nd in the index and 2nd among all Pharmaceutical companies. The rankings are being revealed during the World Economic Forum in Davos today.
The Global 100 Index is a global ranking by Canada-based media and investment advisory company, Corporate Knights, of the top sustainability performers and has come to be recognized as a leader in corporate sustainability analysis. The Global 100 Index is determined from public data using twelve quantitative sustainability indicators which include leadership diversity, employee compensation, tax paid, innovation capacity, and energy and water use, among others.
Shire Chief Executive Officer, Flemming Ornskov, MD, MPH, commented:
“Shire continues to operate with responsibility at the forefront of our business. We are honored to be recognized for the second year as we continue to improve our sustainability initiatives. Our patients depend on us and our products to live better lives, and having an ethical and responsible approach to our daily activities, policies and programs is fundamental to our company, our patients, and the wider global community.”
Read more about Shire’s approach to Responsibility at https://www.shire.com/who-we-are/responsibility
For further information please contact:
Media
Brooke Clarke [email protected]+44 1256 894 829
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.